Background:
- It is not fully understood why prostate cancer in some men becomes
androgen-independent (no longer responds to anti-androgen medication), but genetics
likely plays an important role.
- Genes contain the hereditary information that is passed down from parents to
children. Although everyone has the same set of genes, individuals can have
different forms of the same gene.
- Differences in genes may explain, at least in part, why some people develop a more
aggressive form of prostate cancer than others.
Objectives:
-To obtain blood samples from patients with prostate cancer to try to identify gene
differences associated with progression to the androgen independent state.
Eligibility:
-All participants participating in NCI prostate cancer protocols.
Design:
- Participants with prostate cancer are evaluated in the NCI s Medical Oncology
Clinic.
- Blood samples are collected at the initial visit or at follow-up visits.
- DNA (genetic material) and white blood cells are extracted from these samples to be
used for genotyping and establishment of cell lines.
- Gene variations are correlated with prostate cancer prognosis and prognostic
indicators.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT00923221.
Locations matching your search criteria
United States
Maryland
Bethesda
National Institutes of Health Clinical CenterStatus: Active
Contact: National Cancer Institute Referral Office
Phone: 888-624-1937
Objectives:
-To obtain blood samples from patients with prostate cancer for genotyping analyses.
Eligibility:
- All patients seen in the NCI prostate cancer clinic are eligible.
Design:
- Patients with a prior diagnosis of prostate cancer will be evaluated in the GMB
Clinic, NCI.
- Blood samples will be collected after the participant signs the protocol consent
form. In general, blood will be collected for genomic DNA one time for this study.
Extra samples may be requested if the original sample was not enough. The additional
sample can range from one to two tubes of blood (approximately 2-3 teaspoons total).
Genomic DNA and white blood cells will each be extracted from these samples to be
utilized for genotyping and establishment of individual cell lines.
- Genetic variance will be correlated with prostate cancer prognosis (i.e. time from
diagnosis to death) and prognostic indicators (i.e. histological tumor grade).
- Blood samples for the extraction of cell-free DNA (cfDNA) and cell-free RNA (cfRNA)
may be collected at multiple timepoints for future investigations
- Healthy controls will not be compared and no correlations will be made with prostate
cancer susceptibility.
Trial PhaseNo phase specified
Trial TypeNot provided by clinicaltrials.gov
Lead OrganizationNational Cancer Institute
Principal InvestigatorWilliam Douglas Figg
